ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #niagen--ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program’s (CERP™) 100th published peer-reviewed study on the company’s flagship ingredient Niagen® (patented nicotinamide riboside, or “NR”) and other proprietary ingredients. CERP, the program pioneering NR research, is the first-of-its-kind to reach such a milestone. The recently published...

Click to view original post